Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants

Part of paid clinical trials in Anaheim, California.

Sponsor
Ensho Therapeutics, Inc.
Study ID
NCT07403552
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • NSHO-101 — DRUG
    Dose form - tablet Route of administration - oral Regimen / Treatment period - QD for 14 days

Study Details

The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of NSHO-101 in Healthy Participants.

Key Dates

Start date
Jan 31, 2026
Status verified
Feb 2026
Primary completion
Mar 31, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
24 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Experimental: NSHO-101 Dose A
    Oral dose A of NSHO-101 QD for 14 days
  • Experimental: NSHO-101 Dose B
    Oral dose B of NSHO-101 QD for 14 days

Primary Outcome Measure

Pharmacokinetics: Maximum Concentration (Cmax) [ Time Frame: Day 1 to Day 18 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Cenexel Anaheim CAAnaheimCalifornia92801-

Find similar trials in Anaheim, CA

By research site
Cenexel Anaheim CA· Anaheim, CA

Related Studies